Summary

A proposed CMS rule would close a formulation-switch loophole in Medicare’s drug price negotiation program. Merck’s Keytruda QLEX and Bristol Myers Squibb’s Opdivo Qvantig — subcutaneous versions of established IV immunotherapies — are consequently expected to enter 2029 price negotiations. The federal government will release its list of 20 selected drugs by February 2027. If the rule is finalised, a central commercial strategy for sustaining blockbuster revenue after patent exposure faces a significant pricing constraint. The implications extend beyond these two drugs: any IV-to-subcutaneous switch planned to extend commercial life under Medicare should now be evaluated against this emerging policy risk.

Access Impact

A formulation switch has never been purely clinical. Specifically, when companies transition an IV therapy to subcutaneous administration, they price the new formulation as a value-added alternative — a convenience premium that payers have largely accepted. However, if CMS confirms that subcutaneous reformulations enter the same negotiation pool as their IV predecessors, that pricing model is directly exposed.

The most relevant MARA domain is Budget Impact and Resources. Medicare’s negotiation program targets the highest-spend drugs in Parts B and D. Oncology blockbusters priced at IV-equivalent or above generate significant annual spend. Including subcutaneous formulations in the negotiation pool changes the revenue trajectory materially for both manufacturers.

Cost-Effectiveness

Most HTA bodies have not evaluated subcutaneous and IV formulations as distinct products. As a result, there is no formal evidence base comparing the two administration routes on cost-effectiveness grounds. The pricing argument has rested on convenience and healthcare resource savings. Under CMS negotiation, there is no formal cost-effectiveness threshold — but the absence of comparative clinical evidence could nonetheless reduce negotiating leverage. Moreover, it limits the manufacturer’s ability to differentiate the subcutaneous formulation as a genuinely superior product.

Care-Pathway Integration

Subcutaneous administration reduces infusion centre burden. It also enables care delivery outside the hospital setting — in community clinics or at home — reducing capacity pressure and, in some cases, administration costs. These are genuine pathway benefits. However, in a price negotiation context, care-pathway advantages alone may not justify a sustained price premium if payers classify them as operational rather than clinical gains. The distinction matters: operational benefits are rarely reflected in negotiated drug prices.

Evidence Quality and Robustness

Neither Keytruda QLEX nor Opdivo Qvantig received regulatory approval on the basis of demonstrated clinical superiority over their IV counterparts. Approval relied on pharmacokinetic bridging studies showing comparable drug exposure. Therefore, in a negotiation where CMS considers clinical benefit as part of the assessment, the evidentiary foundation for a subcutaneous price premium is structurally limited. Companies will need to make a resource-use and access argument — a harder case to quantify and defend.

Risk Signal

Formulation strategy is not independent of pricing policy. If CMS finalises this rule, the expected revenue benefit of the IV-to-subcutaneous transition for Keytruda and Opdivo is substantially curtailed. Furthermore, the biosimilar deselection clause adds a second variable: if biosimilar competition materialises before February 2027, CMS can remove all formulations — IV and subcutaneous alike — from the negotiation program entirely. For portfolio teams and investors, the relevant question is whether the commercial value of these subcutaneous formulations under Medicare negotiation has been accurately priced into revenue forecasts. Is the risk already in the model, or is it still treated as a future regulatory event?

#MarketAccess #HTA #MARArating #Medicare

Explore the independent MARA assessment for Pembrolizumab (Keytruda): https://mararating.com/report/pembrolizumab-for-the-first-line-treatment-of-primary-advanced-or-recurrent-endometrial-carcinoma-in-adults-as-of-august-2025/

Explore the independent MARA assessment for Nivolumab (Opdivo): https://mararating.com/report/nivolumab-for-untreated-unresectable-or-metastatic-colorectal-cancer-with-high-microsatellite-instability-or-mismatch-repair-deficiency-as-of-may-2025-market-access-risk-assessment/